2.50
Hdl Handle:
http://hdl.handle.net/10541/72513
Title:
Predicting compliance in a breast cancer prevention trial.
Authors:
Maurice, Andrew; Howell, Anthony ( 0000-0002-3879-5991 ) ; Evans, D Gareth R; O'Neill, Alison C; Scobie, Sue
Abstract:
The impact of chemoprevention trials can be hampered by poor participant compliance with the study medication. We used medication monitoring systems and pill count data to try to establish factors that may predict compliance with the International Breast Intervention Study (IBIS) and whether the participants went on to complete or benefit the trial. Women who took their trial medication in a regular pattern rather than randomly were more likely to be of benefit to the study (p = 0.003). For those women who failed to complete the study, compliance was shown to gradually reduce at each follow-up appointment. The taking of additional prescribed medication and not smoking were important factors in predicting completion (p = 0.04 and p = 0.047, respectively) and benefit (p = 0.037 and p = 0.031, respectively) to the study. Taking these factors into account when advising women at the start of a chemoprevention trial may be helpful in improving compliance.
Affiliation:
Breast Cancer Family History Clinic, Nightingale Center, Withington Hospital, South Manchester University Hospital Trust, Manchester, UK. andrew.maurice@smuht.nwest.nhs.uk
Citation:
Predicting compliance in a breast cancer prevention trial., 12 (5):446-50 Breast J
Journal:
The Breast Journal
Issue Date:
2006
URI:
http://hdl.handle.net/10541/72513
DOI:
10.1111/j.1075-122X.2006.00295.x
PubMed ID:
16958964
Type:
Article
Language:
en
ISSN:
1075-122X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMaurice, Andrew-
dc.contributor.authorHowell, Anthony-
dc.contributor.authorEvans, D Gareth R-
dc.contributor.authorO'Neill, Alison C-
dc.contributor.authorScobie, Sue-
dc.date.accessioned2009-07-06T08:29:49Z-
dc.date.available2009-07-06T08:29:49Z-
dc.date.issued2006-
dc.identifier.citationPredicting compliance in a breast cancer prevention trial., 12 (5):446-50 Breast Jen
dc.identifier.issn1075-122X-
dc.identifier.pmid16958964-
dc.identifier.doi10.1111/j.1075-122X.2006.00295.x-
dc.identifier.urihttp://hdl.handle.net/10541/72513-
dc.description.abstractThe impact of chemoprevention trials can be hampered by poor participant compliance with the study medication. We used medication monitoring systems and pill count data to try to establish factors that may predict compliance with the International Breast Intervention Study (IBIS) and whether the participants went on to complete or benefit the trial. Women who took their trial medication in a regular pattern rather than randomly were more likely to be of benefit to the study (p = 0.003). For those women who failed to complete the study, compliance was shown to gradually reduce at each follow-up appointment. The taking of additional prescribed medication and not smoking were important factors in predicting completion (p = 0.04 and p = 0.047, respectively) and benefit (p = 0.037 and p = 0.031, respectively) to the study. Taking these factors into account when advising women at the start of a chemoprevention trial may be helpful in improving compliance.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemoprevention-
dc.subject.meshDouble-Blind Method-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshPatient Compliance-
dc.subject.meshPatient Dropouts-
dc.subject.meshSelf Administration-
dc.subject.meshTamoxifen-
dc.titlePredicting compliance in a breast cancer prevention trial.en
dc.typeArticleen
dc.contributor.departmentBreast Cancer Family History Clinic, Nightingale Center, Withington Hospital, South Manchester University Hospital Trust, Manchester, UK. andrew.maurice@smuht.nwest.nhs.uken
dc.identifier.journalThe Breast Journalen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.